Novo Nordisk A/S (NVO) shares rose 1% in early trading on Thursday. The company has filed a lawsuit seeking to block Hims & Hers Health Inc. (HIMS) from selling compounded semaglutide. This legal action comes just days after the U.S. Food and Drug Administration and the Department of Health and Human Services indicated that enforcement measures would be taken. Hims has suspended the supply of its oral formulation, and its stock fell 1.5% in early trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.